Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 195 participants.

Also called NCT05682378

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 195 participants (planned count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05682378
  • EudraCT 2022-002316-23
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Brazil, Canada, Czechia, France, Germany, Greece, Hungary, Israel, Italy, Jordan, Lebanon, Malaysia, Netherlands, Norway, Poland, Russia, Slovakia, Slovenia, South Africa, Spain, Switzerland, Taiwan, Türkiye, United Kingdom (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05682378. Allocation not applicable; no masking; primary purpose treatment. Start 2023-02-10 (actual); primary completion 2032-03-25 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies
Acronym
V-PEDS-OLE
Condition
Heterozygous or Homozygous Familial Hypercholesterolemia
Intervention (Drug)
Inclisiran
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct05682378
Content hash
920178ad5798fe47574ca2ec71c216f859dd98a0238392206f5a06752a353e25